Sensitivity of Neuroimaging Indicators in Monitoring the Effects of Interferon Gamma Treatment in Friedreich’s Ataxia

The identification of efficient markers of disease progression and response to possibly effective treatments is a key priority for slowly progressive, rare, neurodegenerative diseases for which no treatment is yet available such as Friedreich’s ataxia. Various imaging modalities have documented spec...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neuroscience 2020-10, Vol.14, p.872-872
Main Authors: Vavla, Marinela, Arrigoni, Filippo, Toschi, Nicola, Peruzzo, Denis, D’Angelo, Maria Grazia, Gandossini, Sandra, Russo, Annamaria, Diella, Eleonora, Tirelli, Stefania, Salati, Roberto, Rufini, Alessandra, Condo, Ivano, Testi, Roberto, Martinuzzi, Andrea
Format: Article
Language:English
Subjects:
Ataxia
Clinical trials
Drug dosages
fMRI
Friedreich’s ataxia
Functional magnetic resonance imaging
Interferon
Medical imaging
Neurodegenerative diseases
Neuroimaging
Neuroscience
Patients
Proteins
resting-state fMRI
Retina
Software
task fMRI
trial
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The identification of efficient markers of disease progression and response to possibly effective treatments is a key priority for slowly progressive, rare, neurodegenerative diseases for which no treatment is yet available such as Friedreich’s ataxia. Various imaging modalities have documented specific abnormalities in Friedreich’s ataxia that could be tracked to provide useful indicators of efficacy in clinical trials. Advanced MRI imaging (DTI, fMRI, rs-fMRI) and retinal imaging (OCT) were tested longitudinally in a small group of Friedreich’s ataxia patients participating an open label clinical trial testing safety and efficacy of 6 month treatment with interferon gamma. While DTI indices documented the slow progression of FA loss, fMRI and rs-fMRI were significantly modified during and after treatment. The fMRI changes significantly correlated with the SARA scale, used to monitor clinical response. OCT documented the known thickness reduction of retinal nerve fiber layer thickness but no change over time. This pilot study provides indications for the potential utility of fMRI and rs-fMRI as ancillary measures in clinical trials for Friedreich’s ataxia.
ISSN:1662-453X
1662-4548
1662-453X
DOI:10.3389/fnins.2020.00872